$Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias$

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia. Thirty-one adults with acute myeloid leukemia (AML) and four adults with acute lymphoblastic le...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2010-11, Vol.28 (33), p.4919-4925
Hauptverfasser:	William Blum, Rebecca B. Klisovic, Heiko Becker, Xiaoxia Yang, Darlene M. Rozewski, Mitch A. Phelps, Ramiro Garzon, Alison Walker, Jason C. Chandler, Susan P. Whitman, John Curfman, Shujun Liu, Larry Schaaf, Jon Mickle, Cheryl Kefauver, Steven M. Devine, Michael R. Grever, Guido Marcucci, and, John C. Byrd
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antigens, CD - analysis Antigens, Differentiation, Myelomonocytic - analysis Antineoplastic Agents - therapeutic use Biological and medical sciences Faze Hematologic and hematopoietic diseases Humans Leukemia, Myeloid, Acute - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Middle Aged Original Reports Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Recurrence Sialic Acid Binding Ig-like Lectin 3 Thalidomide - adverse effects Thalidomide - analogs & derivatives Thalidomide - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!